Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved... It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
- Mechanism
- Curator reviewed
Flupirtine upregulates Bcl-2, increases glutathione levels, activates an inwardly rectifying potassium channel, and delays loss of intermitochondrial membrane calcium retention capacity. Flupirtine acts like a NMDA receptor antagonists, but does not bind to the receptor. One study concluded that the discriminative effects of flupirtine are neither of opioid nor of alpha-1 adrenergic type, but are primarily mediated through alpha-2 adrenergic mechanisms [PMID: 2901483].
- Primary indication
- Investigated for use/treatment in fibromyalgia.Curator reviewed
- Formula / weight
- C15H17FN4O2 · 304.3195 g/mol (avg)
Resolves to
JUUFBMODXQKSTD-UHFFFAOYSA-NSMILESCCOC(=O)NC1=C(N)N=C(NCC2=CC=C(F)C=C2)C=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Flupirtine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account